Ampio Pharmaceuticals, Inc. (ARCA:AMPE) insider have most recently took part in a trading activity. On Sep 19, 2017 Coelho Philip H, Director bought 15,000 shares having total worth of $8,550 at the price of $0.57 per share, following the transaction a total of 90,727 shares owned by Coelho Philip H. Before this latest buy, Coelho Philip H purchased AMPE at 1 other times during the past twelve months, for a total investment of $16,800 at an average of $0.56 per share.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 1 times by insiders. an employee of the company was the buyer in 1 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Ampio Pharmaceuticals, Inc. (ARCA:AMPE) traded up 7.43% on Sep 20, 2017, hitting $0.59. 367,150 shares of the company’s stock traded hands. Ampio Pharmaceuticals, Inc. has a 52 week low of $0.38 and a 52 week high of $4.21. The company’s market cap is $39 million.
Ampio Pharmaceuticals, Inc. was formerly known as Chay Enterprises, Inc. On March 2, 2010, the Company entered into an Agreement and Plan of Merger, with DMI Life Sciences, Inc., a Delaware corporation, or DMI and Chay Acquisitions, Inc., a Delaware corporation and its wholly-owned subsidiary which was incorporated in February 2010. At the closing of the transaction, Chay Acquisitions was merged into DMI and DMI, as the Surviving Corporation, became its wholly-owned subsidiary. As a result, the Company is no longer engaged in the real estate business and its business is now that of DMI. The Company is a development stage company which is engaged in developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat and prevent a range of human diseases including metabolic disorders, cancer and acute and chronic inflammation diseases. On 1 March 2010 the Company changed its name to Ampio Pharmaceuticals, Inc. The Company develops drugs to treat metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The Company’s product pipeline includes certain FDA approved drugs, now targeted at new clinical indications protected by its intellectual property and new molecular entities (NMEs). It is actively exploring partnership, licensing and other collaboration opportunities to maximize its near term and long term product development programs. The Company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018